BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19950569)

  • 1. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
    Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
    Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
    Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW; Teller WM; Heinze E
    Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of glycemic control using NPH insulin sliding scale versus insulin aspart sliding scale in continuously tube-fed patients.
    Cook A; Burkitt D; McDonald L; Sublett L
    Nutr Clin Pract; 2009 Dec; 24(6):718-22. PubMed ID: 19955549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.
    Mathiesen ER; Kinsley B; Amiel SA; Heller S; McCance D; Duran S; Bellaire S; Raben A;
    Diabetes Care; 2007 Apr; 30(4):771-6. PubMed ID: 17392539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
    Raskin P; Guthrie RA; Leiter L; Riis A; Jovanovic L
    Diabetes Care; 2000 May; 23(5):583-8. PubMed ID: 10834413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.